CD274 and head and neck cancer: Approximately, 61.9% head and neck cancer patients treated with PD‐1/PD‐L1 inhibitors in clinical trials experienced at least one adverse event of any grade, and 12.8% head and neck cancer patients had at least one grade ≥3 adverse event.